His primary areas of investigation include Multiple myeloma, Internal medicine, Surgery, Transplantation and Oncology. Michel Attal has researched Multiple myeloma in several fields, including Immunopathology and Dexamethasone. His Internal medicine research integrates issues from Gastroenterology and Pathology.
His Surgery study deals with Urology intersecting with Vincristine. The study incorporates disciplines such as Leukemia and Bone marrow in addition to Transplantation. His Oncology research incorporates elements of Long term survival and Immunology.
Michel Attal mainly focuses on Internal medicine, Multiple myeloma, Oncology, Surgery and Transplantation. His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Leukemia. Much of his study explores Multiple myeloma relationship to Dexamethasone.
His studies in Oncology integrate themes in fields like Salvage therapy, Carfilzomib, Immunology and Daratumumab. His Surgery study combines topics from a wide range of disciplines, such as Bone marrow and Urology. His Transplantation research is multidisciplinary, incorporating elements of Survival rate, Stem cell and Fludarabine.
The scientist’s investigation covers issues in Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Dexamethasone. His studies deal with areas such as Newly diagnosed, Transplantation and Cancer research as well as Multiple myeloma. His study looks at the relationship between Internal medicine and fields such as Stem cell, as well as how they intersect with chemical problems.
Within one scientific family, Michel Attal focuses on topics pertaining to Randomized controlled trial under Oncology, and may sometimes address concerns connected to Meta-analysis. He has included themes like Surgery, Maintenance therapy, Phases of clinical research and Thalidomide in his Lenalidomide study. His work carried out in the field of Surgery brings together such families of science as AL amyloidosis and Urology.
His main research concerns Multiple myeloma, Internal medicine, Lenalidomide, Bortezomib and Transplantation. His study on Autologous stem-cell transplantation and Melphalan is often connected to In patient as part of broader study in Multiple myeloma. His Internal medicine study typically links adjacent topics like Oncology.
His Lenalidomide research incorporates themes from Survival rate, Regimen, Surgery and Progression-free survival. His research in Surgery tackles topics such as Urology which are related to areas like Survival analysis, Prospective cohort study and Neutropenia. His Transplantation research incorporates elements of Thalidomide, Maintenance therapy, Immunology, Hazard ratio and Computed tomography.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto.
The New England Journal of Medicine (1996)
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot.
The New England Journal of Medicine (2003)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker.
The Lancet (2007)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot.
The New England Journal of Medicine (2012)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel.
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano.
The New England Journal of Medicine (2014)
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Jean-Luc Harousseau;Michel Attal;Hervé Avet-Loiseau;Gerald Marit.
Journal of Clinical Oncology (2010)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial
Philippe Moreau;Thierry Facon;Michel Attal;Cyrille Hulin.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: